Spyre Therapeutics Inc. - Asset Resilience Ratio
Spyre Therapeutics Inc. (SYRE) has an Asset Resilience Ratio of 83.83% as of June 2026. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See SYRE current assets to equity ratio to evaluate short-term liquidity relative to the company's equity base.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2015–2025)
This chart shows how Spyre Therapeutics Inc.'s Asset Resilience Ratio has changed over time. For the complete balance sheet picture, see Spyre Therapeutics Inc. assets under control.
Liquid Assets Composition Over Time
This chart breaks down Spyre Therapeutics Inc.'s liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. Read Spyre Therapeutics Inc. debt and liabilities for a breakdown of total debt and financial obligations.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 0% |
| Short-term Investments | $983.34 Million | 83.83% |
| Total Liquid Assets | $983.34 Million | 83.83% |
Asset Resilience Insights
- Very High Liquidity: Spyre Therapeutics Inc. maintains exceptional liquid asset reserves at 83.83% of total assets.
- This level provides strong protection against economic uncertainties but may indicate potential for more aggressive growth investments.
- The company has significant short-term investments, indicating active treasury management.
Spyre Therapeutics Inc. Industry Peers by Asset Resilience Ratio
Compare Spyre Therapeutics Inc.'s asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
CSL Ltd
AU:CSL |
Biotechnology | 0.41% |
|
Vaxcyte Inc
NASDAQ:PCVX |
Biotechnology | 41.54% |
|
Bachem Holding AG
SW:BANB |
Biotechnology | 0.00% |
|
Definium Therapeutics, Inc.
NASDAQ:DFTX |
Biotechnology | 38.51% |
|
Chongqing Zhifei Bio Products
SHE:300122 |
Biotechnology | -0.08% |
|
HLB Co. Ltd
KQ:028300 |
Biotechnology | 3.29% |
|
Sinopep-Allsino Biopharmaceutical Co. Ltd. A
SHG:688076 |
Biotechnology | 2.30% |
|
Zhejiang Ausun Pharmaceutical Co Ltd
SHG:603229 |
Biotechnology | 0.12% |
Annual Asset Resilience Ratio for Spyre Therapeutics Inc. (2015–2025)
The table below shows the annual Asset Resilience Ratio data for Spyre Therapeutics Inc..
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2025-12-31 | 86.25% | $670.81 Million | $777.78 Million | +1.83pp |
| 2024-12-31 | 84.42% | $513.66 Million | $608.48 Million | +40.43pp |
| 2023-12-31 | 43.99% | $150.38 Million | $341.86 Million | +14.69pp |
| 2022-12-31 | 29.30% | $20.85 Million | $71.14 Million | -41.64pp |
| 2021-12-31 | 70.94% | $77.99 Million | $109.93 Million | +36.18pp |
| 2020-12-31 | 34.76% | $56.18 Million | $161.62 Million | -28.59pp |
| 2019-12-31 | 63.35% | $52.70 Million | $83.18 Million | -3.61pp |
| 2018-12-31 | 66.96% | $52.05 Million | $77.74 Million | +0.12pp |
| 2017-12-31 | 66.84% | $37.48 Million | $56.08 Million | +43.35pp |
| 2016-12-31 | 23.49% | $15.75 Million | $67.06 Million | +13.74pp |
| 2015-12-31 | 9.75% | $3.77 Million | $38.65 Million | -- |
About Spyre Therapeutics Inc.
Spyre Therapeutics, Inc., a clinical stage biotechnology company, focuses on developing therapeutics for patients living with inflammatory bowel disease (IBD) and rheumatic diseases. The company develops SPY001, a humanized monoclonal immunoglobulin G1 antibody that is in phase-2 clinical stage designed to bind selectively to the a4ß7 integrin being developed for the treatment of IBD (ulcerative … Read more